Diabetic Kidney Disease Market Report 2025

The diabetic kidney disease market size has grown strongly in recent years. It will grow from $2.67 billion in 2024 to $2.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to early understanding of diabetes complications, advancements in diagnostic techniques, development of ace inhibitors and arbs, clinical trials and treatment protocols, guidelines and disease management protocols.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.56 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, rising global diabetes incidence, focus on disease modification therapies, telehealth and remote care, healthcare policy and reimbursement changes. Major trends in the forecast period include advancements in renal replacement therapies, precision medicine approach, focus on early detection and diagnosis, therapeutic advancements, rise in comorbidities management.

The rising prevalence of chronic kidney disease is anticipated to drive the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) is a long-term condition that leads to a gradual loss of kidney function, resulting in various complications such as high blood pressure, anemia, and bone diseases. Treating chronic kidney diseases necessitates diagnostic and treatment options, which ultimately fuels the expansion of the diabetic kidney disease market. For instance, in June 2023, Kidney Research UK, a prominent charity in the UK, reported that chronic kidney disease affects approximately 7.2 million people in the United Kingdom, representing over 10% of the population. Among these individuals, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are often untreated and asymptomatic. Projections suggest that the total number of individuals with chronic kidney disease in the United Kingdom could rise to 7.61 million by 2033. Thus, the increasing prevalence of chronic kidney disease is propelling the growth of the diabetic kidney disease market.

The growing healthcare expenditure is expected to enhance the growth of the diabetic kidney disease market in the future. Healthcare expenditure refers to the total funds allocated for healthcare-related goods and services within a specific timeframe, typically at a national or institutional level. Increased healthcare spending promotes the adoption of advanced diagnostic technologies, enabling early and accurate detection of diabetic kidney disease and facilitating timely intervention and treatment. For example, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. The UK healthcare expenditure was approximately £292 billion in 2023. Therefore, the rising healthcare expenditure is driving the growth of the diabetic kidney disease market.

Technological advancements emerge as a pivotal trend gaining traction in the diabetic kidney disease market. Companies within this sector embrace novel technologies to fortify their market standing. For instance, in August 2022, Bloom Diagnostics, a US-based organization specializing in diagnostics and healthcare devices, introduced the Bloom Kidney Test. Integrated with the Bloom Smart System, this diagnostic tool evaluates kidney health by measuring cystatin C levels - a reliable indicator of kidney function. Categorizing kidney function into three stages - normal, mildly decreased, and decreased - the Bloom Kidney Test leverages cloud-based algorithms and AI technology within the Bloom Smart System. This integration combines test outcomes with pertinent health data such as medical history, lifestyle, and patient symptoms, facilitating comprehensive analysis and management.

Leading companies in the diabetic kidney disease market are actively innovating by developing new products such as medications tailored for chronic kidney disease (CKD), aiming for wider customer reach, increased sales, and revenue growth. These medications for CKD primarily focus on symptom management, slowing disease progression, and addressing complications arising from impaired kidney function. For instance, Bayer AG, a Germany-based pharmaceutical company, introduced Kerendia in August 2022 - a medication specifically designed to manage CKD associated with diabetes. Kerendia stands out as a non-steroidal, selective mineralocorticoid receptor antagonist, uniquely tailored for individuals with chronic kidney disease linked to type-II diabetes. Offering a distinctive treatment approach, Kerendia holds promise in slowing CKD progression and reducing the risk of kidney failure in this susceptible patient group.

In January 2023, AstraZeneca, a UK-based biotech and pharmaceutical giant, finalized the acquisition of Cincor Pharma Inc. for an undisclosed sum. This strategic move strengthens AstraZeneca's cardiorenal pipeline by integrating CinCor's baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) aimed at lowering blood pressure in treatment-resistant hypertension. Cincor Pharma Inc., a US-based biopharmaceutical company, specializes in developing drugs for kidney disease management. AstraZeneca's acquisition bolsters its portfolio by incorporating innovative solutions such as baxdrostat, further solidifying its position in addressing cardiorenal complications and advancing therapeutic options for kidney disease management.

Major companies operating in the diabetic kidney disease market include AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited.

North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetic kidney disease is a form of renal disease resulting from complications of diabetes, where elevated blood sugar levels lead to kidney damage. The kidneys' blood vessels can be adversely affected by high blood glucose, reducing their functionality.

The primary types of diabetic kidney disease are associated with both type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition characterized by minimal or no insulin production by the pancreas. This deficiency leads to elevated blood sugar levels, causing damage to the nephrons and renal blood vessels. Managing blood sugar levels in type 1 diabetes often requires daily insulin injections. Treatment for diabetic kidney disease includes interventions such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other medical approaches provided in facilities such as hospitals, homecare, specialty centers, and more.

The diabetic kidney disease market research report is one of a series of new reports that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.